keyword
MENU ▼
Read by QxMD icon Read
search

"Chronic lymphocytic leukemia"

keyword
https://www.readbyqxmd.com/read/30235180/highlights-in-chronic-lymphocytic-leukemia-from-the-2018-american-society-of-clinical-oncology-annual-meeting-commentary
#1
Susan M O'Brien
No abstract text is available yet for this article.
July 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30235179/highlights-in-chronic-lymphocytic-leukemia-from-the-2018-american-society-of-clinical-oncology-annual-meeting
#2
(no author information available yet)
No abstract text is available yet for this article.
July 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/30234409/oxidative-stress-in-chronic-lymphocytic-leukemia-still-a-matter-of-debate
#3
Giovanni D'Arena, Elisa Seneca, Ilaria Migliaccio, Vincenzo De Feo, Aldo Giudice, Francesco La Rocca, Mario Capunzo, Gioacchino Calapai, Agostino Festa, Michele Caraglia, Pellegrino Musto, Eugenio Luigi Iorio, Vitalba Ruggieri
There is a large body of evidence showing a strong correlation between carcinogenesis of several types of human tumors, including chronic lymphocytic leukemia (CLL), and oxidative stress (OS). The mechanisms by which OS may promote cancer pathogenesis have not been completely deciphered yet and, in CLL, as in other neoplasms, whether OS is a primary cause or simply a downstream effect of the disease is still an open question. It has been demonstrated that, in CLL, OS concomitantly results from increased reactive oxygen species (ROS) production, mainly ascribable to CLL cells mitochondrial activity, and impaired antioxidant defenses...
September 20, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30233768/a-double-blind-randomized-comparison-study-between-zytux%C3%A2-vs-mabthera%C3%A2-in-treatment-of-cll-with-fcr-regimen-non-inferiority-clinical-trial
#4
Gholamreza Toogeh, Mohammad Faranoush, Seyed Mohsen Razavi, Hassan Jalaeikhoo, Abolghasem Allahyari, Mohammad Reza Ravanbod, Fariba Zarrabi, Vahid Fallahazad, Ehsan Rezaei Darzi, Shadi Sadat Alizadeh Fard
BACKGROUND: Chronic lymphocytic leukemia (CLL) is characterized by accumulation of B cells in blood, lymphoid tissues and bone marrow. Addition of rituximab to CLL chemotherapy regimens has been associated with improved survival. The aim of this study was to establish efficacy and safety of Zytux™ in comparison to MabThera® in treatment of CLL. MATERIALS AND METHODS: Seventy CLL patients who met the criteria for entering the study were randomized into two groups (35 patients in each group)...
April 1, 2018: International Journal of Hematology-oncology and Stem Cell Research
https://www.readbyqxmd.com/read/30231870/ibrutinib-suppresses-lps-induced-neuroinflammatory-responses-in-bv2-microglial-cells-and-wild-type-mice
#5
Hye Yeon Nam, Jin Han Nam, Gwangho Yoon, Ju-Young Lee, Youngpyo Nam, Hye-Jin Kang, Hyun-Ji Cho, Jeongyeon Kim, Hyang-Sook Hoe
BACKGROUND: The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton's tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. However, the potential regulation of neuroinflammatory responses in the brain by ibrutinib has not been comprehensively examined. METHODS: BV2 microglial cells were treated with ibrutinib (1 μM) or vehicle (1% DMSO), followed by lipopolysaccharide (LPS; 1 μg/ml) or PBS...
September 19, 2018: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/30231393/approaches-to-chronic-lymphocytic-leukemia-therapy-in-the-era-of-new-agents-the-conundrum-of-many-options
#6
Nitin Jain, Philip Thompson, Alessandra Ferrajoli, Chadi Nabhan, Anthony R Mato, Susan O'Brien
Three small molecule inhibitors have been approved for the treatment of chronic lymphocytic leukemia (CLL) in the last 4 years. Ibrutinib, idelalisib, and venetoclax are oral agents with excellent efficacy and different toxicity profiles. Issues discussed herein include the current role for chemoimmunotherapy in CLL, the use of oral inhibitors in older patients, and the sequencing of these molecules in daily practice.
May 23, 2018: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/30227427/geographic-hematology-some-observations-in-mexico
#7
REVIEW
Perla R Colunga-Pedraza, Gisela B Gomez-Cruz, Julia E Colunga-Pedraza, Guillermo J Ruiz-Argüelles
In 1963 Jean Bernard introduced the concept of "geographic hematology" and distinguished 2 branches, i.e., "ethnic hematology," which deals with differences between populations, and "environmental hematology," which considers factors such as food habits, infections, and others. Both of these branches have implications in the distribution of hematological diseases worldwide. In comparison with Caucasian populations, in Mexico a significantly higher prevalence of acute lymphoblastic, acute promyelocytic, and acute megakaryoblastic leukemias has been described...
September 18, 2018: Acta Haematologica
https://www.readbyqxmd.com/read/30224718/idelalisib-promotes-bim-dependent-apoptosis-through-akt-foxo3a-in-hepatocellular-carcinoma
#8
Dan Yue, Xun Sun
Idelalisib, a selective PI3Kδ inhibitor, has been approved by the FDA for chronic lymphocytic leukemia/small lymphocytic lymphoma treatment and for follicular lymphoma treatment when combined with rituximab. However, the mechanisms of effective action of idelalisib in hepatocellular carcinoma (HCC) remain unclear. In the current study, we aimed to investigate how idelalisib inhibits the growth of HCC cells and enhances the effects of other chemotherapeutic drugs. Our results show that idelalisib treatment promotes Bim induction in HCC via the FoxO3a pathway following PI3K/AKT inactivation...
September 17, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/30222470/on-the-front-line-first-choice-pharmacotherapeutics-for-chronic-lymphocytic-leukemia
#9
Laura S Samples, Solomon A Graf
Introduction Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with a highly variable clinical course. Frontline treatments include cytotoxic chemotherapies, immunotherapies, and small molecule inhibitors. Clinical and molecular factors guide treatment initiation and selection. Over the last decade, refinement of CLL risk stratification tools and growth of the arsenal of effective therapeutics have profoundly improved outcomes. These advances have concurrently increased the complexity of managing the early phases of treatment...
September 17, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/30221064/high-dimensional-mass-cytometry-analysis-revealed-microenvironment-complexity-in-chronic-lymphocytic-leukemia
#10
Marina Wierz, Bassam Janji, Guy Berchem, Etienne Moussay, Jerome Paggetti
In this study, we extensively dissected the phenotypic complexity of the splenic tumor microenvironment (TME) in chronic lymphocytic leukemia (CLL) by high-dimensional mass cytometry (CyTOF). As a result, we identified potential new targets and tested a dual immune checkpoint blockade targeting the TME in pre-clinical mouse models of CLL.
2018: Oncoimmunology
https://www.readbyqxmd.com/read/30219356/immunoglobulin-replacement-therapy-targeting-the-bcr-in-chronic-lymphocytic-leukemia
#11
Gerardo Ferrer
No abstract text is available yet for this article.
September 12, 2018: EBioMedicine
https://www.readbyqxmd.com/read/30217965/illuminating-aberrant-mrna-events-in-cll
#12
(no author information available yet)
Findings from a recent study suggest that intronic polyadenylation, a form of mRNA processing, is aberrant and widespread in chronic lymphocytic leukemia, targeting multiple genes. This results in truncated proteins that no longer function as effective tumor suppressors and, in some cases, are even oncogenic.
September 14, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30213872/improving-cll-v%C3%AE-9v%C3%AE-2-t-cell-fitness-for-cellular-therapy-by-ex-vivo-activation-and-ibrutinib
#13
Iris de Weerdt, Tom Hofland, Roeland Lameris, Sanne Endstra, Aldo Jongejan, Perry Moerland, Renee Cg de Bruin, Ester B M Remmerswaal, Ineke J M Ten Berge, Nora Liu, Mario van der Stelt, Laura M Faber, Mark-David Levin, Eric Eldering, Sanne H Tonino, Tanja D de Gruijl, Hans J van der Vliet, Arnon P Kater
The efficacy of autologous (αβ)-T cell-based treatment strategies in chronic lymphocytic leukemia (CLL) has been modest. The Vγ9Vδ2T-cell subset comprises of cytotoxic T lymphocytes with potent anti-lymphoma activity via a major histocompatibility complex (MHC)-independent mechanism. We studied whether Vγ9Vδ2-T cells can be exploited as autologous effector lymphocytes in CLL. Healthy control (HC) Vγ9Vδ2-T cells were activated by and had potent cytolytic activity against CLL cells. However, CLL-derived Vγ9Vδ2-T cells proved dysfunctional with respect to effector cytokine production and degranulation, despite an increased frequency of the effector-type subset...
September 13, 2018: Blood
https://www.readbyqxmd.com/read/30213394/an-update-in-treating-transformed-lymphoma
#14
REVIEW
James Godfrey, Michael J Leukam, Sonali M Smith
Indolent lymphomas typically have a prolonged course and favorable prognosis. Recent data support survival times that can reach several decades, even if periodic treatment is needed to manage symptoms or stabilize disease. However, all indolent lymphomas have the potential to undergo transformation to an aggressive phenotype, clinically characterized by a rapid progression of adenopathy, new-onset constitutional symptoms, or laboratory abnormalities, and the immediate need for therapeutic intervention. The most common scenario is transformation of follicular lymphoma to either diffuse large B-cell lymphoma or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations; however, other indolent subtypes such as marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia, or even nodular lymphocyte predominant Hodgkin lymphoma, can undergo similar histologic transformation...
September 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/30211723/differential-outcomes-among-immunosuppressed-patients-with-merkel-cell-carcinoma-impact-of-immunosuppression-type-on-cancer-specific-and-overall-survival
#15
Maclean Cook, Kelsey Baker, Mary Redman, Kristina Lachance, Macklin H Nguyen, Upendra Parvathaneni, Shailender Bhatia, Paul Nghiem, Yolanda D Tseng
OBJECTIVES: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with higher incidence among whites, elderly, and immunosuppressed patients. Although immunosuppressed MCC patients are at higher risk of recurrence and MCC-related death, it is unknown whether immunosuppression type is associated with differential outcomes. MATERIALS AND METHODS: We retrospectively evaluated 89 nonmetastatic MCC patients with a diagnosis of chronic immunosuppression...
September 11, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/30210797/kaposi-s-sarcoma-in-an-hiv-negative-chronic-lymphocytic-leukemia-patient-without-immunosuppressive-therapy-a-case-report
#16
Damir Vučinić, Andrea Dekanić, Gordana Zamolo, Margita Belušić-Gobić, Ingrid Belac-Lovasić, Tanja Batinac
Kaposi's sarcoma is a neoplasm of endothelial cells. That vascular tumor is usually limited to the skin, but it may involve mucous membranes, visceral organs, and lymph nodes. Serological evidence has shown that human herpesvirus 8 infection is required for the development of Kaposi's sarcoma. Chronic lymphocytic leukemia is the most common leukemia all over the world. Increased skin cancer risk has been reported for patients with chronic lymphocytic leukemia. The relation between these two pathologies has not yet been clarified...
2018: SAGE Open Medical Case Reports
https://www.readbyqxmd.com/read/30210236/targeting-the-autophagy-in-bone-marrow-stromal-cells-overcomes-resistance-to-vorinostat-in-chronic-lymphocytic-leukemia
#17
Lu Ding, Wan Zhang, Lili Yang, Helene Pelicano, Kaiwen Zhou, Ran Yin, Ruibin Huang, Junyi Zeng
Background: The bone marrow microenvironment constitutes a sanctuary for leukemia cells. Recent evidence indicates that environment-mediated drug resistance arises from a reciprocal influence between tumor cells and the surrounding stroma. The present study aimed to investigate the effect of chronic lymphocytic leukemia (CLL) cells on the metabolism of bone marrow stroma, to determine the role of this metabolic change in the stroma in vorinostat resistance of CLL cells, and thus to assess a novel strategy to target stroma and achieve the maximum therapeutic effect of vorinostat...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/30199912/-individualized-treatment-of-chronic-lymphocytic-leukemia-cll
#18
Julia von Tresckow, Michael Hallek, Barbara Eichhorst
Because of the excellent prognosis in early asymptomatic stage of the disease all patients outside clinical trial should undergo "watch & wait" independently of their individual risk profile. Prognostic markers and scoring systems, as the CLL international prognostic index (CLL-IPI), help predicting the individual prognosis. In advanced stage disease standard frontline therapy in patients without high risk factors is still the combination of chemotherapy and CD20-antibody. However, particularly elderly patients with unfavorable prognostic factors may alternatively be treated with the Btk-inhibitor...
September 2018: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/30196472/tlr2-expression-on-leukemic-b-cells-from-patients-with-chronic-lymphocytic-leukemia
#19
Agata Szymańska, Agnieszka Bojarska-Junak, Arkadiusz Drobiecki, Waldemar Tomczak, Jacek Roliński, Marek Hus, Iwona Hus
Antigenic stimulation is considered as a possible trigger of neoplastic transformation in chronic lymphocytic leukemia (CLL). B-cell receptor plays a key role in the interactions between the microenvironment and leukemic cells; however, an important role has also been attributed to Toll-like receptors (TLRs). It is believed that disorders of TLR expression may play a part in the pathogenesis of CLL. In this study, we investigated the potential role of TLR2 in CLL by analyzing its expression on leukemic B cells in correlation with clinical and laboratory parameters characterizing disease activity and patients' immune status...
September 8, 2018: Archivum Immunologiae et Therapiae Experimentalis
https://www.readbyqxmd.com/read/30192023/diagnostic-framing-of-igm-monoclonal-gammopathy-focus-on-waldenstr%C3%A3-m-macroglobulinemia
#20
REVIEW
Alessandra Tedeschi, Concetta Conticello, Rita Rizzi, Giulia Benevolo, Luca Laurenti, Maria Teresa Petrucci, Francesco Zaja, Marzia Varettoni
The finding of an IgM monoclonal gammopathy often represents a diagnostic challenge. In fact, there are many pathological disorders associated with this condition, each of which has distinctive characteristics and requires specific clinical, instrumental, and laboratory assessments to set the appropriate treatment. This review has two aims. Firstly, to provide a framework of the broad spectrum of IgM-associated disorders: (1) monoclonal gammopathy of undetermined significance (MGUS); (2) Waldenström macroglobulinemia (WM); (3) IgM-related disorders (among which hyperviscosity syndrome, light chain amyloidosis, cold agglutinin disease, cryoglobulinaemia, IgM neuropathy, Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (POEMS) syndrome, Castleman disease); (4) IgM-secreting multiple myeloma (IgM-MM); and (5) other lymphoproliferative disorders which may be associated with IgM (such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and B-cell non Hodgkin lymphoma)...
September 7, 2018: Hematological Oncology
keyword
keyword
108143
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"